NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen

Zhaorui Song; Yongkuan Suo; Shuang Duan; Shanshan Zhang; Lifu Liu; Botong Chen; Zhen Cheng

doi:10.1016/j.bios.2023.115063

NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen

Biosens Bioelectron. 2023 Mar 15:224:115063. doi: 10.1016/j.bios.2023.115063. Epub 2023 Jan 4.

Authors

Zhaorui Song¹, Yongkuan Suo², Shuang Duan³, Shanshan Zhang⁴, Lifu Liu⁴, Botong Chen⁴, Zhen Cheng⁵

Affiliations

¹ Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
² Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China; Institute of Molecular Medicine Joint Laboratory for Molecular Medicine Northeastern University, Shenyang, Liaoning, 110000, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
³ State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
⁴ Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China.
⁵ Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. Electronic address: zcheng@simm.ac.cn.

PMID: 36610190
DOI: 10.1016/j.bios.2023.115063

Abstract

Fluorescent lateral flow immunoassay (LFA) is one of the most common analytical platforms for point-of-care testing (POCT), which is capable of facile and early screening of biomarkers. Notably, fluorescent probes play a decisive role in analytical performances of LFA. Herein, we report a novel LFA based on the rare earth doped nanoparticles (RENPs) emitting in the second near-infrared (NIR-II) window for the detection of biomarkers, such as carcinoembryonic antigen (CEA). Benefiting from the dual fluorescent emission at NIR-II window, strong fluorescent penetration, low autofluorescence and excellent photostability of RENPs, this proposed NIR-II LFA displays a good linear relationship ranging from 1 to 320 ng mL^-1. The detection limit is as low as 0.37 ng mL^-1, which is of 13.5 times lower than the clinical cutoff value. Overall, NIR-II LFA biosensing platform based RENPs not only exhibits high sensitivity, accuracy and specificity, but also have characteristics of rapidity, simplicity and low cost. It holds high potential for early diagnosis of tumor biomarkers in POCT.

Keywords: Carcinoembryonic antigen; Immunoassay; NIR –II; Point-of-care testing; Rare earth doped nanoparticles.

MeSH terms

Biomarkers, Tumor
Biosensing Techniques*
Carcinoembryonic Antigen
Fluorescent Dyes
Nanoparticles*
Point-of-Care Testing
Spectroscopy, Near-Infrared

Substances

Biomarkers, Tumor
Carcinoembryonic Antigen
Fluorescent Dyes